We evaluated the prognostic relevance of several clinical and laboratory parameters in 226 Mayo Clinic patients with chronic myelomonocytic leukemia (CMML): 152 (67%) males and median age 71 years. At a median follow-up of 15 months, 166 (73%) deaths and 33 (14.5%) leukemic transformations were documented. In univariate analysis, significant risk factors for survival included anemia, thrombocytopenia, increased levels of white blood cells, absolute neutrophils, absolute monocyte count (AMC), absolute lymphocytes, peripheral blood and bone marrow blasts, and presence of circulating immature myeloid cells (IMCs). Spliceosome component (P ¼ 0.4) and ASXL1 mutations (P ¼ 0.37) had no impact survival. On multivariable analysis, increased AMC (410 Â 10 9 /l, relative risk (RR) 2.5, 95% confidence interval (CI) 1.7-3.8), presence of circulating IMC (RR 2.0, 95% CI 1.4-2.7), decreased hemoglobin (o10 g/dl, RR 1.6, 99% CI 1.2-2.2) and decreased platelet count (o100 Â 10 9 /l, RR 1.4, 99% CI 1.0-1.9) remained significant. Using these four risk factors, a new prognostic model for overall (high risk, RR 4.4, 95% CI 2.9-6.7; intermediate risk, RR 2.0, 95% CI 1.4-2.9) and leukemia-free survival (high risk, RR 4.9, 95% CI 1.9-12.8; intermediate risk, RR 2.6, 95% CI 1.1-5.9) performed better than other conventional risk models and was validated in an independent cohort of 268 CMML patients.
INTRODUCTION
Chronic myelomonocytic leukemia (CMML) is a clonal, hematopoietic stem cell disorder, with overlapping features of myelodysplastic syndromes (MDSs) and myeloproliferative neoplasms. CMML is characterized by persistent peripheral blood (PB) monocytosis 41 Â 10 9 /l, absence of the BCR-ABL1 fusion, absence of rearrangements of the PDGFRA or PDGFRB genes, absence of X20% myeloblasts or promonocytes in the blood and bone marrow (BM) and presence of dysplasia in one or more myeloid lineages. 1 Based on the 2008 World Health Organization (WHO) classification system, CMML is further subcategorized into CMML-1 (o5% circulating blasts and o10% BM blasts) and CMML-2 (5-19% circulating blasts, 10-19% BM blasts or when Auer rods are present irrespective of the blast count), with median overall survivals (OSs) of approximately 20 and 15 months, respectively. 1, 2 Numerous prognostic models have attempted to risk stratify patients with CMML. In this regard, the value of Bournemouth, Lille and the International Prognostic Scoring Systems (IPSS) is limited, as they were designed primarily for patients with MDS, excluding CMML patients with a proliferative phenotype. [3] [4] [5] The MD Anderson Prognostic Scoring System (MDAPS) was developed in a cohort of 213 CMML patients and identified a hemoglobin level o12 g/dl, presence of circulating immature myeloid cells (IMCs), absolute lymphocyte count (ALC) 42.5 Â 10 9 /l andX10% BM blasts as independent predictors for inferior survival. 6 This model identified four subgroups of patients with median survivals of 24, 15, 8 and 5 months respectively. 6 The MDAPS was subsequently applied to 212 CMML patients in the Dusseldorf registry; 7 in a univariate analysis, circulating IMC had no prognostic impact, whereas on multivariable analysis, elevated lactate dehydrogenase, BM blast count 410%, male gender, hemoglobin o12 g/dl and ALC 42.5 Â 10 9 /l were independently prognostic. 7 The Dusseldorf score classified patients into three risk categories, with median survivals of 93 (low), 26 (intermediate) and 11 (high) months, respectively. 7 The Spanish cytogenetic riskstratification system analyzed the role of karyotype in patients with CMML. 8 Based on their analysis, three cytogenetic risk categories were identified: low risk (diploid karyotype or loss of chromosome Y as a single anomaly), intermediate risk (all other abnormalities except those mentioned in low-and high-risk categories) and high risk (trisomy 8, abnormalities of chromosome 7 or complex karyotype); with 5-year OS for the three groups being 35%, 26% and 4%, respectively (Po0.001). 8 This stratification system did not predict leukemic transformation (LT). 8 In 2008, the Global MDAPS (G-MDAPS) was developed for patients with de novo MDS, secondary MDS and CMML (n ¼ 1915). 9 On a multivariable analysis, independent prognostic factors included older age, poor performance status, thrombocytopenia, anemia, increased BM blasts, leukocytosis (420 Â 10 9 /l), chromosome 7 or complex cytogenetic abnormalities and a prior history of red blood cell transfusions.
176 patients with CMML and leukocytosis (412 Â 10 9 /l), with median survivals in the four risk categories being 33, 19, 12 and 8 months, respectively (Po0.01); 9 limitations for G-MDAPS included the inclusion of patients with upto 30% BM blasts (oligoblastic AML).
Molecular abnormalities are detected in B90% of patients with CMML. 10, 11 These are broadly categorized into mutations involving epigenetic regulators (EZH2, ASXL1, TET2, DNMT3A, IDH1 and  IDH2) , 10, 12, 13 spliceosome components (SF3B1, SRSF2, U2AF35 and ZRSR2), 1, 14, 15 DNA-damage response genes (TP53) 16 and transcription regulators and signaling molecules (JAK2, KRAS, NRAS, NPM1 and RUNX1). 11, 17 Thus far, in CMML, loss-of-function gene mutations involving ASXL1 and EZH2 has been associated with poor outcome. 12, 15 Given the inconsistency among currently available CMML prognostic models, their lack of strict adherence to the WHO classification system when selecting study patients and the discovery of molecular abnormalities potentially having an impact on survival, we undertook the current study with 226 single-center study patients strictly defined by the WHO, fully annotated for karyotype and also analyzed for reportedly prognostic somatic mutations. We then validated the results in an independent cohort of 268 patients from the H. Lee Moffitt Cancer Center in Tampa, Florida.
MATERIALS AND METHODS
The current study was approved by the Mayo Clinic institutional review board. Study eligibility criteria included availability of PB smear, BM histology and cytogenetic information at the time of referral to the Mayo Clinic. The diagnoses of CMML, including subclassification into CMML-1 or CMML-2, and documentation regarding the presence or absence of ring sideroblasts and LT were according to the 2008 WHO criteria. 1 All complete blood count differentials and PB smears were evaluated for presence of circulating IMCs, defined by the presence of any of the following cells in circulation: myeloblasts, myelocytes, metamyelocytes and promyelocytes. 6 Karyotype risk designation and CMML risk stratification were according to the Spanish cytogenetic risk-stratification system, 8 the MDAPS 6 and the G-MDAPS, respectively. 9 In the analysis of prognostic factors, variables included were age, sex, hemoglobin, white blood cell count (WBC), absolute neutrophil count, absolute monocyte count (AMC), ALC, platelet count, PB and BM blasts, circulating IMC, BM cellularity, percentage of BM ring sideroblasts, WHO morphological subcategories (CMML-1 vs CMML-2), karyotype groups based on the Spanish cytogenetic risk-stratification system, MDAPS and G-MDAPS prognostic risk categories, ASXL1 mutations and spliceosome component mutations, involving SF3B1, SRSF2 and U2AF35 (also referred to as U2AF1).
At the time of CMML diagnosis, DNA from BM or PB was extracted using conventional methods. ASXL1, SF3B1 and SRSF2 mutation analysis was performed according to previously published methods. [19] [20] For detection of U2AF35 mutations, we applied the standard PCR techniques and bidirectional sequencing. For U2AF35, we amplified two areas with known mutations that included residues S34 and Q157. Briefly, two separate PCR reactions were performed and the primers used were as follows: ( All statistical analyses considered clinical and laboratory parameters obtained at the time of referral to the Mayo Clinic, which in most instances coincided with time of BM biopsy at the Mayo Clinic and study sample collection. Differences in the distribution of continuous variables between categories were analyzed by either Mann-Whitney (for comparison of two groups) or Kruskal-Wallis (comparison of three or more groups) test. Patient groups with nominal variables were compared by w 2 -test. OS was calculated from the date of first referral to date of death (uncensored) or last contact (censored). Leukemia-free survival was calculated from the date of first referral to the date of LT (uncensored) or death/last contact (censored). Overall and leukemia-free survival curves were prepared by the Kaplan-Meier method and compared by the log-rank test. Cox proportional hazard regression model was used for multivariable analysis. P-values o0.05 were considered significant. The Stat View (SAS Institute, Cary, NC, USA) statistical package was used for all calculations.
RESULTS
Two-hundred and twenty-six patients with WHO-defined CMML and who were seen at the Mayo Clinic from 1997 to 2007 were included in the current study. The median age of the cohort was 71 years (range 20-90 years), with 67% of the patients being males. Table 1 outlines the presenting clinical and laboratory features and subsequent events in the 226 study patients with CMML, stratified by PB and BM blasts. One-hundred and ninetyone patients (84%) had CMML-1 with a median OS of 21 months, whereas 35 patients had CMML-2 with a median OS of 15 months.
Patients with CMML-2 were more likely to have lower hemoglobin levels (P ¼ 0.04), higher AMC (P ¼ 0.03), lower platelet counts (P ¼ 0.0007), higher likelihood of circulating blasts and IMC (Po0.0001), and higher risk of karyotypic abnormalities (Po0.0001). They were also more likely to be assigned higher risk scores based on the MDAPS and the G-MDAPS. There, however, was no difference in the distribution of ASXL1 and spliceosome component mutations (Table 1) .
One-hundred and fifty (66%) patients had a diploid karyotype, whereas 11 (5%) had no Y chromosome. Seven (3%) patients had an abnormality of chromosome 7 (monosomy 7-6 and del7q-1), 16 (7%) had þ 8 (9 as a single abnormality and 7 with an additional structural abnormality), 8 (4%) had a monosomal karyotype and 2 (1%) patients had a complex karyotype without monosomies. Other cytogenetic abnormalities included del20q-5 (2%), þ 21-3 (1%), þ 14-2 (1%), þ 11-2 (1%) and isochromosome 17q-2(1%). Eighteen patients (8%) had chromosomal translocations that did not fit into any specific category. Fluorescence in situ hybridization testing for BCR-ABL1 and PDGFRA/B was negative in all cases. The Spanish cytogenetic risk-stratification system identified 163 (72%) patients in the low-risk category, 31 (14%) in the intermediate-risk category and 32 (14%) in the high-risk category, respectively. There was no difference in outcomes in a comparison between CMML patients with a monosomal karyotype and those with a complex karyotype without monosomies.
ASXL1 mutations were detected in 87 (49%) out of 179 analyzed patients, 72% (63) being male, with a median age of 70 years (range 27-86 years). The most common ASXL1 mutation was c.1934dupG;p.Gly646TrpfsX12 (n ¼ 47, 54%), followed by the 1900_1922_ del seen in 10 (11%) patients. Table 2 describes the ASXL1 mutational prevalence in 179 patients with CMML. ASXL1-mutated patients were found to have a higher WBC (P ¼ 0.009), higher AMC (P ¼ 0.008), higher prevalence of circulating IMC (P ¼ 0.03) and were more likely to have concomitant mutations of the U2AF35 gene (P ¼ 0.03). There was no difference in age (P ¼ 0.6), gender (P ¼ 0.23), hemoglobin values (P ¼ 0.07), platelet count (P ¼ 0.09), ALC (P ¼ 0.79), PB (P ¼ 0.5) and BM (0.27) blasts, WHO histological categories (P ¼ 0.3) and the incidence of SRSF2 (P ¼ 0.57) and SF3B1 (P ¼ 0.43) mutations. Prognostic risk stratification using the Spanish cytogenetic risk-stratification system (P ¼ 0.17), MDAPS (P ¼ 0.2) and the G-MDAPS (0.32) demonstrated no difference between mutated and unmutated patients. Thirty-seven (42%), 13 (14%) and 2 (2%) patients had concomitant ASXL1 and SRSF2, U2AF35 and SF3B1 mutations, respectively. Because of the question on whether c.1934dupG;p.-Gly646TrpfsX12 is truly an ASXL1 gene mutation vs a somatic alteration, 12 we reanalyzed the entire cohort, excluding the 47 patients with this mutation and found no difference in our results (Supplementary figure one). Sixteen ASXL1 mutations were novel and have not been reported to date (Table 2) . ASXL1 mutations had no effect on the OS (P ¼ 0.37) or leukemia free survival (0.09) ( Table 3 and Figure 1 ).
Ninety patients (40%) had SRSF2 mutations, 13 (6%) had SF3B1 mutations and 20 (9%) had U2AF35 mutations. One-hundred and twenty-three (54%) patients had at least one of the three spliceosome mutations. Notably, all three spliceosome mutations were mutually exclusive. There was no statistically significant difference, among the three mutation groups (SRSF2 vs SF3B1 vs U2AF35), in prognostically relevant parameters. 1 The only notable difference was that patients with the SF3B1 mutations had a higher percentage of BM ring sideroblast (Po0.0001), lower median WBC (P ¼ 0.04) and a lower ALC (P ¼ 0.045). In univariate analysis, the presence of SRSF2, SF3B1 or U2AF35 mutations had no prognostic impact on OS or leukemia free survival (Table 3 and Figure 1 ). 1 At a median follow-up of 15 months, considering all 226 patients, 176 (78%) deaths and 32 (14%) LTs were documented. Median survivals were 22 months for CMML-1 and 14 months for CMML-2. On a univariate analysis, factors adversely influencing OS included high WBC (Po0.0001), high absolute neutrophil count (P ¼ 0.0005), high ALC (P ¼ 0.005), high AMC (Po0.0001), low platelet count (P ¼ 0.012), presence of circulating IMC (Po0.0001), PB blasts (P ¼ 0.002), BM blasts (P ¼ 0.005), BM cellularity (P ¼ 0.01), WHO morphological categories (P ¼ 0.02), MDAPS (Po0.0001), G-MDAPS (P ¼ 0.01) and the Spanish cytogenetic risk-stratification system (P ¼ 0.04) ( Table 3 ). As mentioned above, ASXL1 and spliceosome component mutations had no impact on OS. On multivariable analysis that included the aforementioned variables, only increased AMC (410 Â 10 9 /l, relative risk (RR) 2.5, 95% confidence interval (CI) 1.7-3.8), presence of circulating IMC (RR 2.0, 95% CI 1.4-2.7), decreased hemoglobin (o10 g/dl, RR 1.6, 99% CI 1.2-2.2) and decreased platelet count (o100 Â 10 9 /l, RR 1.4, 99% CI 1.0-1.9) retained significance. Using these four independent risk factors, we prepared a new prognostic risk model consisting of three risk categories: low risk (0 risk factors), intermediate risk (one risk factor) and high risk (two or more risk factors), with median survivals of 32, 18.5 and 10 months, respectively (Figure 2) . The Mayo prognostic model performed better than the MDAPS, G-MDAPS and the Spanish cytogenetic risk models (Figure 2 ). This model was also predictive of LT: high risk, RR 4.9 (95% CI 1.9-12.8) and intermediate risk, RR 2.6 (1.1-5.9). Individual parameters of independent significance for LT included PB blast count and AMC 410 Â 10 9 /l. The Mayo prognostic model Abbreviations: ALC, absolute lymphocyte count; AMC, absolute monocyte count; ANC, absolute neutrophil count; ASXL1, additional sex combs 1 gene; BM, bone marrow; CMML, chronic myelomonocytic leukemia; PB, peripheral blood; SF3B1, splicing factor 3B subunit 1; SRSF2, serine/arginine-rich splicing factor 2; U2AF35, U2 small-nuclear RNA auxiliary factor 1; WBC, white blood cell count. *ASXL1 gene sequencing was limited to 179 patients, 150 with CMML-1 and 29 with CMML-2, because of limited availability of DNA. 
DISCUSSION
The presence of overlapping features between MDS and myeloproliferative neoplasm has given rise to ambiguity with regard to diagnosis and prognostication of patients with CMML. A number of prognostic systems are either based on the old French-American-British classification of CMML (Bournemouth, Modified Bournemouth and Lille) or are not primarily designed for CMML (IPSS, revised IPSS and G-MDAPS). [3] [4] [5] 21 The commonly used MDAPS was developed on a cohort of 213 CMML patients and identified four risk groups based on the hemoglobin level, presence of IMC, ALC and BM blasts. 6 The adverse prognostic value conferred by these factors was validated by the Dusseldorf model, with the exception of circulating IMC. 7 In addition, the Dusseldorf scoring system identified elevated lactate dehydrogenase and male gender as negative prognosticators for survival. 7 In general, high ALC have been associated with favorable outcomes in hematological malignancies, and its inclusion as an adverse prognosticator in the MDAPS is perplexing. 10, 22 In our study, high ALC, although prognostic in a univariate analysis, lost its prognostic significance on a multi variable analysis. In addition, contrary to the aforementioned models, we found that a high AMC was independently associated with a shortened OS. The G-MDAPS was developed for patients with de novo MDS, secondary MDS and CMML and identified older age, poor performance status, thrombocytopenia, anemia, increased BM blasts, leukocytosis, chromosome 7 or complex cytogenetic abnormalities and transfusion dependence as independent factors associated with a shorter OS. 9 In our study, although the G-MDAPS stratified patients into four risk categories, the Mayo prognostic model was more effective and was able to risk stratify within each of the G-MDAPS risk groups.
Approximately 20-40% of patients with CMML have an abnormal karyotype. 1, 8 In our study, 76 (34%) had an abnormal karyotype, with prominent aberrations being 11 (5%) with À Y, 7 (3%) with abnormalities of chromosome 7 (monosomy 7-6 and del 7q-1), 16 (7%) with þ 8, 8 (4%) with a monosomal karyotype and 2 (1%) with a complex karyotype. Although the Spanish cytogenetic risk-stratification system was prognostic on a univariate analysis, it lost its prognostic impact on a multivariable analysis. In addition, unlike AML and MDS, where a monosomal karyotype has been associated with worse outcomes compared with a complex karyotype, this difference was not seen in our CMML cohort. 11, 23 Large numbers of genetic aberrations have been identified in patients with CMML. 10, 11 Of these, mutations involving ASXL1 and EZH2 have been associated with poor outcomes. 12, 15 The ASXL1 (additional sex combs like 1) gene, contains 12 exons and maps to chromosome 20q11, regulating epigenetic functions and transcription. 24 ASXL1 mutations are common in myeloid malignancies, including MDS, 13, 20 AML, 13 myeloproliferative neoplasm 16 and CMML. 17, 25 In CMML, B40% of patients have ASXL1 mutations, with the most frequent aberration being c.1934dupG;p.Gly646TrpfsX12. 17, 20, 25 Although one study has described this as a PCR artefact, 12 as it is not found in germline DNAs, control DNAs or other studied types of cancers, it is generally considered to be a bona fide mutation. 25 In our study, 87 (49%) patients had an ASXL1 mutation, with 47 (28%) of these being c.1934dupG;p.Gly646TrpfsX12. ASXL1 mutations were associated with a proliferative phenotype, higher WBC, higher AMC and presence of circulating IMC. However, on a univariate analysis, they had no impact on either the OS or the leukemia free survival. Given the controversy surrounding the c.1934dupG;p.Gly646TrpfsX12 ASXL1 mutation, we reanalyzed our cohort after excluding these patients and found no differences in our observations. Similarly, as published by our group before, spliceosome component mutations involving SF3B1, SRSF2 and U2AF35 are common in CMML, and do not have an impact on either the OS or the leukemia free survival.
1
SF3B1 mutations are commonly associated with myeloid neoplasms expressing ring sideroblasts. 1, 18 We performed a survival analysis utilizing multiple clinical, pathological and molecular variables. We included commonly used prognostic scoring systems such as MDAPS, G-MDAPS and the Spanish cytogenetic risk-stratification system. On a multivariable analysis, only increased AMC (410 Â 10 9 /l, RR 2.5, 95% CI 1.7-3.8), presence of circulating IMC (RR 2.0, 95% CI 1.4-2.7), decreased hemoglobin (o10 g/dl, RR 1.6, 99% CI 1.2-2.2) and decreased platelet count (o100 Â 10 9 /l, RR 1.4, 99% CI 1.0-1.9) retained significance. Using these four independent risk factors, we prepared the Mayo prognostic model for CMML, consisting of three risk categories: low risk (0 risk factors), intermediate risk (one risk factor) and high risk (two or more risk factors), with median survivals of 32, 18.5 and 10 months, respectively ( Figure 2) . This model was validated in an independent cohort of 268 CMML patients at the H. Lee Moffitt Cancer Center, in Tampa, Florida. In our cohort of CMML patients, the Mayo prognostic model outperformed the MDAPS, G-MDAPS and the Spanish cytogenetic risk models.
